Research programme: signal transduction pathway inhibitors - Amgen/U3 Pharma

Drug Profile

Research programme: signal transduction pathway inhibitors - Amgen/U3 Pharma

Alternative Names: U3-1800

Latest Information Update: 22 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen; U3 Pharma
  • Class Antibodies
  • Mechanism of Action Receptor protein-tyrosine kinase antagonists; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 26 May 2008 U3 Pharma has been acquired by Daiichi Sankyo Company
  • 17 Apr 2008 This programme is still in active development
  • 03 Apr 2006 Abgenix has been acquired and merged into Amgen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top